

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:


LISTING OF CLAIMS:

Claim 1 (Original): A method for preventing or treating allergic diseases, comprising administering an effective amount of black rice extract to an individual in need thereof.

Claim 2 (Original): The method of claim 1, wherein the black rice extract comprises pelargonidin represented by Formula 1 or cyanidin glycoside represented by Formula 2.


Claim 3 (Original): A method for preventing or treating allergic diseases, comprising administering an effective amount of pelargonidin represented by Formula 1, pharmaceutically acceptable salts or glycosides thereof to an individual in need thereof.

<Formula 1>



Claim 4 (Original): A method for preventing or treating allergic diseases, comprising administering an effective amount of cyanidin glycoside (cyanidin 3-O- β -glucopyranoside) represented by Formula 2 or pharmaceutically acceptable salts thereof to an individual in need thereof.

<Formula 2>



Claim 5 (Original): A method for inhibiting the accumulation of eosinophiles in cells, tissues or a body, comprising administering pelargonidin represented by Formula 1, pharmaceutically acceptable salts or glycosides thereof to an individual in need thereof.

Claim 6 (Original): A method for inhibiting the accumulation of eosinophiles in cells, tissues or a body, comprising administering cyanidin glycoside represented

by Formula 2 or pharmaceutically acceptable salts thereof to an individual in need thereof.

Claim 7 (Currently Amended): The method of ~~anyone of claims 1 to 4~~ claim 1, wherein the allergic disease is selected from a group consisting of bronchial asthma, chronic obstructive pulmonary disease, hay fever, vasomotor rhinitis, hypertrophic rhinitis, allergic bronchitis, transient pulmonary infiltration, allergic gastritis, allergic diarrhea, allergic stomatitis, intestinal purpura, periarteritis nodosa, occlusive endarteritis, angina pectoris, endocarditis, urticaria, angioneurotic edema, erythema nodosum, purpura, atopic dermatitis, phlycten, sympathetic ophthalmia, allergic conjunctivitis and allergic keratitis.

Claim 8 (Original): The method of claim 7, wherein the allergic disease is bronchial asthma or chronic obstructive pulmonary disease.

Claim 9 (Original): A composition for preventing or treating allergic diseases comprising one or more selected from a group consisting of black rice extract, pelargonidin represented by Formula 1 or cyanidin glycoside represented by Formula 2.

Claim 10 (Currently Amended): A ~~use of black rice extract~~ method for the preparation of a therapeutic agent for preventing or treating allergic diseases comprising using black rice extract.

Claim 11 (Currently Amended): A ~~use of pelargonidin, pharmaceutically acceptable salts or glycosides thereof~~ method for the preparation of a therapeutic agent for preventing or treating allergic diseases comprising using pelargonidon, pharmaceutically acceptable salts or glycosides thereof.

Claim 12 (Currently Amended): A ~~use of cyanidin glycoside (cyanidin 3-O- β -glucopyranoside)~~ method for the preparation of a therapeutic agent for preventing or treating allergic diseases comprising using cyaniding 3-O- β -glucopyranside).

Claim 13 (Currently Amended): The ~~use of anyone~~ method of claim 10 ~~claims 10 to 12~~, wherein the allergic disease is selected form a group consisting of bronchial asthma, chronic obstructive pulmonary disease, hay fever, vasomotor rhinitis, hypertrophic rhinitis, allergic bronchitis, transient pulmonary infiltration, allergic gastritis, allergic diarrhea, allergic stomatitis, intestinal purpura, periarteritis nodosa, occlusive endarteritis, angina pectoris, endocarditis, urticaria, angioneurotic edema, erythema nodosum, purpura, atopic dermatitis, phlycten, sympathetic ophthalmia, allergic conjunctivitis and allergic keratitis.

Claim 14 (Currently Amended): A ~~use of pelargonidin represented by Formula 1, pharmaceutically acceptable salts or glycosides thereof~~ method for the preparation of a therapeutic agent for inhibiting the accumulation of eosinophiles in cells, tissues or an individual in need thereof comprising using pelargonidin represented by Formula 1, pharmaceutically acceptable salts or glycosides thereof.

Claim 15 (Currently Amended): A ~~use of cyanidin glycoside represented by~~
~~Formula 2 or pharmaceutically acceptable salts thereof~~ method for the preparation of
a therapeutic agent for inhibiting the accumulation of eosinophiles in cells, tissues or
individual in need thereof comprising using cyaniding glycoside represented by
Formula 2 or pharmaceutically acceptable salts thereof.